BRISTOL MYERS SQUIBB
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Study of Immunotherapy to Treat Advanced Prostate Cancer
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 988
- Registration Number
- NCT00861614
- Locations
- ๐บ๐ธ
Southern Cancer Center, Mobile, Alabama, United States
๐บ๐ธArizona Clinical Research Center, Inc., Tucson, Arizona, United States
๐บ๐ธLoma Linda University Cancer Center, Loma Linda, California, United States
Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole
- Conditions
- Alzheimer Disease
- Interventions
- First Posted Date
- 2009-03-12
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 30
- Registration Number
- NCT00860275
- Locations
- ๐บ๐ธ
Ppd Development, Lp, Austin, Texas, United States
First Line Hepato Cellular Carcinoma (HCC)
- Conditions
- Hepato Cellular Carcinoma (HCC)
- Interventions
- First Posted Date
- 2009-03-10
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1714
- Registration Number
- NCT00858871
- Locations
- ๐บ๐ธ
Agajanian Institute Of Hematology And Oncology, Downey, California, United States
๐บ๐ธSharp Clinical Oncology Research, San Diego, California, United States
๐บ๐ธJames Graham Brown Cancer Center, Louisville, Kentucky, United States
Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment
- First Posted Date
- 2009-03-10
- Last Posted Date
- 2015-10-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 46
- Registration Number
- NCT00859053
- Locations
- ๐บ๐ธ
Orlando Clinical Research Center, Orlando, Florida, United States
๐บ๐ธAdvanced Clinical Research Institute, Anaheim, California, United States
Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer
- First Posted Date
- 2009-03-04
- Last Posted Date
- 2010-02-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 36
- Registration Number
- NCT00855764
Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer (CRC)
- Interventions
- First Posted Date
- 2009-02-25
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 17
- Registration Number
- NCT00851045
- Locations
- ๐บ๐ธ
Midwest Center For Hematology/Oncology, Joliet, Illinois, United States
๐บ๐ธPharma Resource, East Providence, Rhode Island, United States
๐บ๐ธCompassionate Cancer Care Medical Group Inc, Fountain Valley, California, United States
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2009-02-25
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 255
- Registration Number
- NCT00850577
- Locations
- ๐บ๐ธ
Palm Beach Cancer Institute, West Palm Beach, Florida, United States
๐บ๐ธClintell, Inc., Skokie, Illinois, United States
๐บ๐ธNorth Canton Medical Clinic Center, Canton, Ohio, United States
An Experimental Medicine Study to Evaluate Serum Biomarkers of Lipid Metabolism
- Conditions
- Atherosclerosis
- Interventions
- Procedure: Blood draw
- First Posted Date
- 2009-02-19
- Last Posted Date
- 2009-11-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 150
- Registration Number
- NCT00847782
- Locations
- ๐จ๐ฆ
Local Institution, Montreal, Quebec, Canada
A Study of BMS-863233 in Patients With Hematologic Cancer
- Conditions
- Refractory Hematologic Cancer
- Interventions
- Drug: Cdc7-inhibitor (BMS-863233)
- First Posted Date
- 2009-02-09
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 11
- Registration Number
- NCT00838890
- Locations
- ๐บ๐ธ
Massachusetts General Hospital, Boston, Massachusetts, United States
๐บ๐ธH. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
๐บ๐ธRoswell Park, Buffalo, New York, United States
Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-779788 in Healthy Subjects
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2011-02-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT00836602
- Locations
- ๐ฆ๐บ
Local Institution, Heidelberg, Victoria, Australia